Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
|Official Title:||Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer|
|Study Start Date:||December 2005|
|Study Completion Date:||February 2008|
|Primary Completion Date:||February 2008 (Final data collection date for primary outcome measure)|
This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future.
This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic (over-expression, amplification, point mutations, etc.) and phenotypic alterations of other transduction pathways interacting with the EGFR pathway.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00298064
|United States, New Mexico|
|University of New Mexico|
|Albuquerque, New Mexico, United States, 87131|
|Principal Investigator:||Claire Verschraegen, MD||University of New Mexico|